Supriya Lifescience Limited — Investor Meet, 31-01-2025: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Supriya Lifescience reported robust Q3 results, with revenue from operations growing by 33% YoY to INR 186 crore, driven by high demand across its product lines. The company achieved an EBITDA margin of 35.5%, up 591 bps, reflecting operational efficiency and focus on high-margin products. Profit after tax surged by 57% YoY to INR 47 crore, resulting in a PAT margin of 25%, a significant increase from 21.1% the previous year.

**Future Outlook and Growth Drivers:** Management emphasized plans to launch new products in therapeutic segments like anesthetics and anti-diabetic drugs. The expansion into regulated markets, particularly in LATAM, North America, and Africa, underpins their growth trajectory. The company aims for 20% revenue growth and aspires to double its revenue to INR 1,000 crore by FY '27.

**Order Book and Operational Updates:** The recent commissioning of the Module E block has added to the production capacity, supporting future growth objectives. The company is also progressing in launching new products while maintaining a firm pipeline for advanced API and contract manufacturing opportunities.

**Analyst Q&A Insights:**

- **Revenue and Profitability:** Analysts sought clarity on revenue expectations with management indicating stable growth, especially with significant contributions projected from advanced intermediates and new geographic markets.

- **Market Position and Competitive Landscape:** Questions concerning competitive threats reaffirmed Supriya's focus on backward integration and maintaining supply chain security, thereby securing pricing stability despite potential market pressures.

- **Operational Challenges or Risks:** Management expressed confidence in overcoming challenges like supply chain issues due to a solid backward integrated business model.

- **Capex and Capital Allocation:** Planned capital expenditures are estimated at INR 120-130 crore, aimed at facility refurbishments and R&D expansions for innovative products.

- **Strategic Priorities and Long-Term Vision:** The focus continues on innovation, particularly in niche API segments while exploring opportunities in contrast media and novel therapeutic areas.

**Market or Regulatory Updates:** Engagements in LATAM are notable, contributing 21% to total revenue, confirming registration with regulatory bodies to boost market penetration.

**Strategic Focus Areas:** Management's commitment to operational excellence and product innovation signals positive market sentiment towards Supriya's potential performance.

**Investor Insight:** Given the financial strength, growth prospects, and strategic initiatives, the company presents a compelling case for a 'buy' position, supported by robust forward guidance and market expansion plans.